Armidale's cannabis mother plants are originally sourced from Canada. Seedlings propogated from clippings grow into junior stock to be put into the green houses and grown out to the flowering stage.

Flowers are be dried, cured, and packaged in the parmicutical grade facility for export striaght agross to Germany. The whole process is surrounded by heavy bio-security procedures and security and safety measures.

In Germany the flowers are available on prescription to patients.

ANTG founder and manager Matt Cantelo said production in Armidale was about to expand, which meant the number of workers was about to double to 30.

"Phase two of our manufacturing is going to be moving further into other forms of finished product, such as, oils, soft gel caps, powders, and we'll also have a seperate lab on site for genetics," he said.

"We'll be expanding our manufacturing capabilities quite considerably over the next 12 months at that site.

ALSO READ:

"I suspect once we hit full-swing in Armidale we'll be pushing 60 plus staff as we ramp up."

Mr Cantelo thought the overseas market for the company's product held a great deal of promise.

"The European market is quite large. Germany's population alone is 90 odd million," he said.

"And the fact that we've got EU distribution rights, France and other countries around that have large populations.

"I believe the Europen cannabis market is growing considerably over the next few years. I believe it's touted to be pushing the 12 billion by about 2028."

Mr Cantelo said the EU was a great place to be exporting produce to and highlighting Australain produce in.

Matt Cantelo was living in Denver, Colorado in 2011-12 when the medical regulations surrounding cannabis changed in the US, and he saw many wonderful results.

He began researching when he returned to Australia in 2013. He surrounded himself with cannabis expertise and ANTG was formed in 2015.